Scientific Program Committee

Monday
February 4 Sessions
Session 13 CROI 2008
c Monday, 2-3 pm; Room 302-304
CME
Session 13–Poster Discussion
(see Session 137 on Tuesday for corresponding Poster Abstracts)
Emerging Patterns of Resistance to New
Antiretrovirals
Discussants:
Victoria Johnson, Univ of Alabama at Birmingham, US
Rob Schuurman, Univ Med Ctr Utrecht, The Netherlands
869 An Enhanced Version of the Trofile HIV Co-receptor
Tropism Assay Predicts Emergence of CXCR4 Use in
ACTG5211 Vicriviroc Trial Samples
Jacqueline Reeves* 1 , D Han 1 , T Wilkin 2 , T Wrin 1 , D Kuritzkes 3 ,
C Petropoulos 1 , J Whitcomb 1 , N Parkin 1 , R Gulick 2 , and E Coakley 1
1 Monogram Biosci, South San Francisco, CA, US; 2 Weill Med Coll of
Cornell Univ, New York, NY, US; and 3 Brigham and Women’s Hosp,
Cambridge, MA, US
870 Emergence in vivo of Vicriviroc Resistance in HIV-1
Subtype C: Role of V3 Loop and Susceptibility to Other
CCR5 Antagonists
Athe Tsibris* 1,2 , M Sagar 2,3 , Z Su 4 , C Flexner 5 , W Greaves 6 , P Skolnik 7 ,
E Coakley 8 , M Subramanian 9 , R Gulick 10 , and D Kuritzkes 2,3
1 Massachusetts Gen Hosp, Boston, US; 2 Harvard Med Sch, Boston, MA,
US; 3 Brigham and Women’s Hosp, Boston, MA, US; 4 Harvard Sch of
Publ Hlth, Boston, MA, US; 5 Johns Hopkins Univ, Baltimore, MD, US;
6 Schering-Plough Res Inst, Kenilworth, NJ, US; 7 Boston Med Ctr, MA,
US; 8 Monogram Biosci, South San Francisco, CA, US; 9 Human Genome
Sci, Rockville, MD, US; and 10 Weill Med Coll of Cornell Univ, New York,
NY, US
871 Changes in V3 Loop Sequence Associated with Failure
of Maraviroc Treatment in Patients Enrolled in the
MOTIVATE 1 and 2 Trials
Marilyn Lewis* 1 , J Mori 1 , P Simpson 1 , J Whitcomb 2 , X Li 3 , D Roberston 1 ,
and M Westby 1
1 Pfizer Global R&D, Sandwich Labs, Kent, UK; 2 Monogram Biosci, South
San Francisco, CA, US; and 3 Faculty of Life Sci, Univ of Manchester, UK
872 Naturally Occurring Polymorphisms in HIV-1 Group M, N,
and O Integrase: Implications for Integrase Inhibitors
John Hackett*, B Harris, V Holzmayer, J Yamaguchi, KC Luk,
C Brennan, G Schochetman, S Devare, and P Swanson
Abbott Diagnostics, Abbott Park, IL, US
873 Development of vircoTYPE HIV-1 Resistance Analysis,
Including Clinical Cutoffs for TMC125, a New NNRTI
Bart Winters* 1 , J Vingerhoets2 , M Peeters2 , J Villacian1 ,
E Van Craenenbroeck1 , and L Bacheler3 1 2 Virco BVBA, Mechelen, Belgium; Tibotec BVBA, Mechelen, Belgium;
and 3VircoLab Inc, Durham, NC, US
874 Characterization of Virologic Failures on Darunavir/
Ritonavir in the Randomized, Controlled, Phase III TITAN
Trial in Treatment-experienced Patients
Sandra De Meyer* 1 , E Lathouwers1 , I Dierynck1 , E De Paepe1 ,
B Van Baelen1 , T Vangeneugden1 , S Spinosa-Guzman1 , G Picchio2 , and
MP de Bethune1 1 2 Tibotec BVBA, Mechelen, Belgium and Tibotec Inc, Yardley, PA, US
8 15th Conference on Retroviruses and Opportunistic Infections
e Monday, 4-6 pm; Room 302-304
CME
Session 14–Oral Abstracts
PMTCT
Moderators:
Grace Aldrovandi, Children’s Hosp Los Angeles and Univ of Southern California, US
Wafaie Fawzi, Harvard Sch of Publ Hlth, Boston, MA, US
4:00 42LB Extended Infant Post-exposure Prophylaxis with
Antiretroviral Drugs Significantly Reduces Postnatal
HIV Transmission: The PEPI-Malawi Study
Taha Taha* 1 , M Thigpen2 , N Kumwenda1 , D Hoover3 , G Kafulafula4 ,
Q Li1 , L Mipando5 , K Nkanaunena5 , M Fowler6 , and L Mofenson7 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore,
MD, US; 2CDC, Atlanta, GA, US; 3Rutgers Univ, Piscataway, NJ,
US; 4Univ of Malawi Coll of Med, Blantyre; 5Johns Hopkins Univ
Coll of Med, Blantyre, Malawi; 6Johns Hopkins Univ Sch of Med,
Baltimore, MD, US; and 7Natl Inst of Child Hlth and Human Devt,
NIH, Bethesda, MD, US
4:15 43 Extended-dose Nevirapine to 6 Weeks of Age for
Infants in Ethiopia, India, and Uganda: A Randomized
Trial for Prevention of HIV Transmission through
Breastfeeding
Jayagowri Sastry* 1,2,3,4 and the SWEN Study Team
1 2 BJ Med Coll, Pune, India; Johns Hopkins Univ, Baltimore, MD,
US; 3Addis Ababa Univ Faculty of Med, Ethiopia; and 4Makerere Univ Sch of Med, Kampala, Uganda
4:30 44 Timing of Infection Is Critical for Nevirapine
Resistance Outcomes among Breastfed Subtype C HIV-
1-infected Infants Exposed t o Extended vs Single-dose
Nevirapine Prophylaxis: The India SWEN Study
Anitha Moorthy* 1 , A Gupta2 , J Sastry3 , V Venkatramani4 ,
R Bhosale4 , V Kulkarni3 , N Gupte3 , C Ziemniak2 , R Bollinger2 , and
D Persaud2 on behalf of the India SWEN Study Team
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD,
US; 2Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 3BJ Med
Coll and Johns Hopkins Univ, Pune, India; and 4BJ Med Coll, Pune,
India
4:45 45aLB PMTCT of HIV-1 among Breastfeeding Mothers Using
HAART: The Kisumu Breastfeeding Study, Kisumu,
Kenya, 2003-2007
Timothy Thomas* 1 , R Masaba2 , R Ndivo2 , C Zeh1 , C Borkowf3 ,
M Thigpen3 , K De Cock1 , P Amornkul1 , A Greenberg3 , M Fowler3 ,
and Kisumu Breastfeeding Study Team
1 2 3 CDC Kenya, Kisumu; Kenya Med Res Inst, Kisumu; and CDC,
Atlanta, GA, US
5:00 45b The TEmAA ANRS 12109 Phase II Trial, Step 1:
Tolerance and Viral Resistance after Single-dose
Nevirapine and Short-course of Tenofovir Disoproxil
Fumarate and Emtricitabine to Prevent Mother-to-
Child Transmission of HIV-1
Elise Arrive* 1 , ML Chaix2 , E Nerrienet3 , S Blanche4 , C Rouzioux2 ,
J McIntyre5 , P Coffie6 , K Sim7 , D Ekouevi6 , and F Dabis1 1INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor
Segalen, Bordeaux, France; 2Ctr Hosp Univ Necker, Univ Paris
Descartes, Paris, France; 3Inst Pasteur, Phnom Penh, Cambodia;
4 5 Hosp Necker for Sick Children, Paris, France; Univ of the
Witwatersrand, Soweto, South Africa; 6Prgm PACCI, Abidjan Côte
d’Ivoire; and 7Hosp Calmette, Phnom Penh, Cambodia
5:15 46 Duration and Pattern of Breastfeeding and Postnatal
Transmission of HIV: Pooled Analysis of Individual
Data from a West and South African Cohort Study
Renaud Becquet* 1,2,3 , R Bland1,4 , V Leroy2,3 , N Rollins1,5 ,
D Ekouevi2,3,6 , A Coutsoudis5 , F Dabis2,3 , H Coovadia7 ,
R Salamon2,3 , and ML Newell1,8 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu
Natal, Somkhele, South Africa; 2INSERM U593, Bordeaux, France;
3Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, Bordeaux,
France; 4Univ of Glasgow, UK; 5Univ of KwaZulu Natal, Durban,
South Africa; 6Ctr Hosp Univ of Treichville, Abidjan, Côte d’Ivoire;
7Ctr for HIV/AIDS Networking, Univ of KwaZulu Natal, Durban,
South Africa; and 8Ctr for Pediatric Epi and Biostatistics, Inst of
Child Hlth, Univ Coll London, UK
5:30 47LB Population Pharmacokinetics of Tenofovir in HIV-
1-infected Pregnant Women and Their Neonates:
TEmAA ANRS 12109
Deborah Hirt* 1,2 , S Urien1,2 , E Rey1 , D Ekouevi3 , S Blanche2 ,
G Gray4 , P Coffie3 , K Leang Sim5 , F Dabis6 , and JM Treluyer1,2 1 2 3 Hosp Cochin, France; Univ Paris Descartes, France; Prgm
PACCI, Abidjan, Côte d’Ivoire; 4Univ of the Witwatersrand,
Soweto, South Africa; 5Hosp Calmette, Phnom Penh, Cambodia;
and 6INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor
Segalen, Bordeaux, France